
Experts say revakinagene taroretcel-lwey approval may represent dawn of new treatments for neurodegenerative conditions
The approval of revakinagene taroretcel-lwey (Encelto; Neurotech Pharmaceuticals) as the first and only FDA-approved treatment for macular telangiectasia type 2 (MacTel) marks a significant milestone for patients with the progressive retinal disease.1 The …